ArQule Gets U.S. Patent

ArQule said pre-market Wednesday that the U.S. Patent and Trademark Office has issued U.S. Patent on composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S. for the allowed claims.

ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The company plans to begin a phase 1 clinical trial by Q3 with ARQ 531 in patients with B-cell malignancies who are refractory to other therapeutic options.

Leave a Comment